Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | APLNR | P35414 | 1/20 | 0.39 |
| ▸ | TBXAS1 | P24557 | 9/20 | 0.35 |
| ▸ | IDO1 | P14902 | 2/20 | 0.35 |
| ▸ | AGXT | P21549 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.34 |
| ▸ | TUBB | P07437 | 1/20 | 0.34 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.34 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.34 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.34 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.34 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.34 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.34 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.34 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7096896 | 1.00 | CA1 (0.40) | CA1CA2APLNRTBXAS1IDO1 | |
| SCHEMBL7198518 | 0.89 | CA1 (0.40) | CA1CA2APLNRTBXAS1IDO1 | |
| SCHEMBL7198525 | 0.89 | CA1 (0.40) | CA1CA2APLNRTBXAS1IDO1 | |
| SCHEMBL7530664 | 0.88 | CA1 (0.37) | CA1CA2TSHR | |
| SCHEMBL14619682 | 0.88 | CA1 (0.41) | CA1CA2APLNRTBXAS1IDO1 | |
| SCHEMBL6807121 | 0.87 | CA1 (0.41) | CA1CA2APLNRTBXAS1IDO1 | |
| SCHEMBL7190403 | 0.87 | CA1 (0.41) | CA1CA2APLNRTBXAS1IDO1 | |
| SCHEMBL6807118 | 0.87 | CA1 (0.41) | CA1CA2APLNRTBXAS1IDO1 | |
| SCHEMBL7190398 | 0.87 | CA1 (0.41) | CA1CA2APLNRTBXAS1IDO1 | |
| SCHEMBL6810807 | 0.87 | CA1 (0.38) | CA1CA2APLNRTBXAS1IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8030503-B2 | Process for the preparation of epothilones | KOSAN BIOSCIENCES INCORPORATED (US) | 2011-10-04 | — | — | US | disclosed |
| US-20080319211-A1 | PROCESS FOR THE PREPARATION OF EPOTHILONES | KOSAN BIOSCIENCES, INC. (US) | 2008-12-25 | — | — | US | disclosed |
| US-7148218-B2 | Certain substituted polyketides, pharmaceutical compositions containing them and their use in treating tumors | NOVARTIS AG (CH) | 2006-12-12 | — | — | US | disclosed |
| US-20050080080-A1 | Certain substituted polyketides, pharmaceutical compositions containing them and their use in treating tumors | KINDER FREDERICK R (US) | 2005-04-14 | — | — | US | disclosed |
| US-6833367-B2 | A polyhydroxy-polymethyl-8-tridecenoic acid 8-lactone compounds, as antitumor agents, anticarcinogenic agents | NOVARTIS AC (CH) | 2004-12-21 | — | — | US | disclosed |
| US-20040018598-A1 | Bio-intermediates for use in the chemical synthesis of polyketides | SANTI DANIEL (US) | 2004-01-29 | — | — | US | disclosed |
| US-20030153601-A1 | Certain substituted polyketides, pharmac eutical compositions containing them and their use in treating tumors | NOVARTIS AG (CH) | 2003-08-14 | — | — | US | disclosed |
| EP-1312608-A2 | Discodermolide analogues and their pharmaceutical use | Novartis AG (CH) | 2003-05-21 | — | — | EP | disclosed |
| EP-1307579-A2 | BIO-INTERMEDIATES FOR USE IN THE CHEMICAL SYNTHESIS OF POLYKETIDES | Kosan Biosciences, Inc. (US) | 2003-05-07 | — | — | EP | disclosed |
| US-20020052028-A1 | Bio-intermediates for use in the chemical synthesis of polyketides | KOSAN BIOSCIENCES, INC. | 2002-05-02 | — | — | US | disclosed |
| WO-2002012534-A2 | BIO-INTERMEDIATES FOR USE IN THE CHEMICAL SYNTHESIS OF POLYKETIDES | KOSAN BIOSCIENCES, INC. (US) | 2002-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030153601-A1 | Certain substituted polyketides, pharmac eutical compositions containing them and their use in treating tumors | PBK, BCKDK, ETV6 | CA1 3468/4885CA2 3541/4885APLNR 2647/4885 |
| US-20050080080-A1 | Certain substituted polyketides, pharmaceutical compositions containing them and their use in treating tumors | PBK, HCCS, BCKDK | CA1 3636/4885CA2 3160/4885APLNR 2030/4885 |
| US-20040018598-A1 | Bio-intermediates for use in the chemical synthesis of polyketides | DHPS, FDFT1, COASY | CA1 4802/4885CA2 4856/4885APLNR 2576/4885 |
| US-20080319211-A1 | PROCESS FOR THE PREPARATION OF EPOTHILONES | DHPS, EPOR, PPOX | CA1 4488/4885CA2 4855/4885APLNR 2482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.